The Peficitinib Diaries
tazemetostat will lower the extent or outcome of pazopanib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.Otesezonale, a BCRP inhibitor, may well enhance the outcomes and possibility of toxicities of BCRP substrates. Use most affordable commencing dose of BCRP substrate, or take into account minimizing BCRP substrate